Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Due to this analysis, it is important for the patients who are candidates for sipuleucel-T to receive it early in their treatment course since that is where the best outcomes were seen, explains Sartor.

This could lead to the hypothesis that perhaps African-American patients are more responsive to immunotherapy across many different cancer types, but this needs to be proven, states Sartor.